In Singapore, a growing number of people are turning to diabetes medications like Ozempic and Wegovy as a way to lose weight. While these drugs are clinically proven to help manage blood sugar and obesity, medical professionals are increasingly concerned about their use as a casual weight-loss hack. The medications, known as GLP-1 receptor agonists, mimic hormones that regulate appetite and satiety, making them highly effective for those with specific medical needs. However, the rise in popularity has led to concerns about their use by individuals without underlying health conditions who are simply seeking a shortcut to a thinner body.
Data from the Ministry of Health shows a significant increase in the use of semaglutide injections, with the number of patients rising from approximately 1,500 in 2023 to 6,400 in 2025. This surge is attributed to both greater public awareness and increased familiarity among doctors in prescribing these treatments. While these drugs are powerful tools for managing chronic conditions like Type 2 diabetes and obesity, they are not without side effects, which can include nausea and digestive issues. Doctors emphasize that these medications should be part of a medically supervised plan rather than a standalone solution.
Experts point out that the cultural narrative surrounding these drugs often overlooks the importance of long-term lifestyle changes. There is a fear that viewing these medications as a quick fix could lead to unrealistic expectations and potential health risks if used without proper guidance. As demand continues to rise, the focus remains on ensuring that these life-changing treatments remain accessible to the patients who need them most, while also educating the public on the risks of off-label or inappropriate use. Moving forward, the medical community will likely continue to monitor the situation closely to balance patient access with safety.